dNovo is developing a proprietary direct reprogramming system to generate new, personalized hair stem cells to replace cells lost due to aging or conditions such as male patterned baldness. Using its proprietary technology, dNovo has converted human skin cells directly into induced hair stem cells without going through a pluripotent state.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/24/22 | $2,700,000 | Seed |
Felicis Ventures SOMA Capital Y Combinator Yintai Investment Company | undisclosed |
